American Association for Cancer Research
crc-22-0468_fig1.png (434.32 kB)

FIGURE 1 from Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans

Download (434.32 kB)
posted on 2023-05-15, 14:20 authored by Wonkyung Oh, Alyssa Min Jung Kim, Deepika Dhawan, Perry M. Kirkham, Raluca Ostafe, Jackeline Franco, Uma K. Aryal, Robert H. Carnahan, Valery Patsekin, J. Paul Robinson, Deborah W. Knapp, Seung-Oe Lim

Working flow chart for production and validation of the cPD-L1 antibody. A, Immunization of antigen, cPD-L1 protein. B, Establishment of hybridomas (over 2,000 clones). C, Evaluation of the cPD-L1 specific antibody by the live cell–based antibody binding assay. D, Therapeutic antibody selection by cPD-L1/cPD-1 blockade assay. E,In vivo validation of therapeutic efficacy of cPD-L1 antibodies in the caninized PD-L1 mice. F, Production of the cPD-L1 chimeric antibody. G, Validation of the cPD-L1 chimeric antibody. H, Initial safety profile and PK analysis. PK, pharmacokinetic.


Leidos Biomedical Research Inc. Research Contract

Purdue EVPRP Office

HHS | National Institutes of Health (NIH)

HHS | NIH | National Cancer Institute (NCI)



Our cPD-L1 antibody and unique caninized mouse model will be critical research tools to improve the efficacy of immune checkpoint blockade therapy in both dogs and humans. Furthermore, these tools will open new perspectives for immunotherapy applications in cancer as well as other autoimmune diseases that could benefit a diverse and broader patient population.